Export file:

Format

  • RIS(for EndNote,Reference Manager,ProCite)
  • BibTex
  • Text

Content

  • Citation Only
  • Citation and Abstract

Tyramine activates lipid accumulation in rat adipocytes: influences of in vitro and in vivo administration

1 Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale (INSERM U1048), I2MC, 31432 Toulouse Cedex 4, France
2 Université Paul Sabatier, I2MC-UPS, CHU Rangueil, Toulouse, France
3 present address: Health Sciences, Universidad San Jorge, Villanueva de Gállego, Zaragoza, Spain
4 present address: LBNB, Alimentomica, Universitat de les Illes Balears, Palma de Mallorca, Spain

Tyramine is naturally occurring in foods. This biogenic amine is known to induce hypertension, especially when ingested by individuals treated by irreversible inhibitors of monoamine oxidases (MAO). However, in animals, tyramine is also an agonist for trace amine-associated receptors and substrate of semicarbazide-sensitive amine oxidases (SSAO). Though tyramine can alter aminergic transmission by various mechanisms, it was recently reported that prolonged tyramine supplementation does not deteriorate glucose tolerance and does not cause adverse cardiovascular effects in mice. Since previous studies have described insulin-like effects of tyramine in fat cells from diabetic rats, we have further tested tyramine in vitro and in vivo actions on fattening. To this aim, antilipolytic and lipogenic responses to insulin and tyramine were first compared in rat adipocytes while tyramine oxidation was compared in adipose and intestinal tissues. Then, effects of repeated intraperitoneal injections of tyramine (17 µmol/kg/day) on adiposity and on adipocyte functions were studied in young and mature rats. Millimolar doses of tyramine inhibited glycerol release by adipocytes with a maximal antilipolytic effect comparable to that of insulin. Repeated tyramine administration enhanced fat deposition in epididymal white adipose tissue, irrespective of the age of treated rats. This effect was not accompanied by desensitization to lipogenic activation by insulin, tyramine or hydrogen peroxide. Lastly, tyramine was more readily oxidized in adipose than in intestinal tissues when enzymatic activity was expressed per mg of protein. Moreoever, MAO mostly contributed to oxidative deamination in gut while SSAO was predominant in fat. Thus, both short-term and prolonged effects of tyramine were evidencing somewhat insulin-like actions in adipose tissue and led to reconsider the risk/benefit ratio of the dietary intake of this amine.
  Figure/Table
  Supplementary
  Article Metrics

Keywords adipocytes; monoamine oxidase; semicarbazide-sensitive amine oxidase; obesity; glucose homeostasis; vanadium; glycerol

Citation: Francisco Les, Zsuzsa Iffiú-Soltész, Josep Mercarder, Christian Carpéné. Tyramine activates lipid accumulation in rat adipocytes: influences of in vitro and in vivo administration. AIMS Molecular Science, 2017, 4(3): 339-351. doi: 10.3934/molsci.2017.3.339

References

  • 1. Maguire JJ, Parker WA, Foord SM, et al. (2009) International Union of Pharmacology. LXXII. Recommendations for trace amine receptor nomenclature. Pharmacol Rev 61: 1-8.
  • 2. Fankhauser C, Charieras T, Caille D, et al. (1994) Interaction of MAO inhibitors and dietary tyramine: a new experimental model in the conscious rat. J Pharmacol Toxicol Methods 32: 219-224.    
  • 3. Cantarini MV, Painter CJ, Gilmore EM, et al. (2004) Effect of oral linezolid on the pressor response to intravenous tyramine. Br J Clin Pharmacol 58: 470-475.    
  • 4. DeMarcaida JA, Schwid SR, White WB, et al. (2006) Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 21: 1716-1721.    
  • 5. Finberg JP, Gillman K (2011) Selective inhibitors of monoamine oxidase type B and the "cheese effect". Int Rev Neurobiol 100: 169-190.    
  • 6. Marquet A, Kupas K, Johne A, et al. (2012) The effect of safinamide, a novel drug for Parkinson's disease, on pressor response to oral tyramine: a randomized, double-blind, clinical trial. Clin Pharmacol Ther 92: 450-457.
  • 7. Gillman PK (2016) Monoamine Oxidase Inhibitors: a review concerning dietary tyramine and drug interactions. PsychoTropical Commentaries 1: 1-90.
  • 8. Tiller JW, Dowling JT, Tung LH, et al. (1985) Tyramine-induced cardiac arrhythmias. N Engl J Med 313: 266-267.
  • 9. Komprda T, Sladkova P, Dohnal V (2009) Biogenic amine content in dry fermented sausages as influenced by a producer, spice mix, starter culture, sausage diameter and time of ripening. Meat Sci 83: 534-542.    
  • 10. Ubaldo JC, Carvalho AF, Fonseca LM, et al. (2015) Bioactive amines in Mozzarella cheese from milk with varying somatic cell counts. Food Chem 178: 229-235.    
  • 11. Rumore MM, Roth M, Orfanos A (2010) Dietary tyramine restriction for hospitalized patients on linezolid: an update. Nutr Clin Pract 25: 265-269.    
  • 12. Jansen SC, Van Dusseldorp M, Bottema KC, et al. (2003) Intolerance to dietary biogenic amines: a review. Ann Allergy Asthma Immunol 91: 233-240.    
  • 13. Shen SH, Wertz DL, Klinman JP (2012) Implication for functions of the ectopic adipocyte copper amine oxidase (AOC3) from purified enzyme and cell-based kinetic studies. PLoS One 7: e29270.    
  • 14. Visentin V, Prevot D, Marti L, et al. (2003) Inhibition of rat fat cell lipolysis by monoamine oxidase and semicarbazide-sensitive amine oxidase substrates. Eur J Pharmacol 466: 235-243.    
  • 15. Marti L, Morin N, Enrique-Tarancon G, et al. (1998) Tyramine and vanadate synergistically stimulate glucose transport in rat adipocytes by amine oxidase-dependent generation of hydrogen peroxide. J Pharmacol Exp Ther 285: 342-349.
  • 16. Carpéné C, Daviaud D, Boucher J, et al. (2006) Short- and long-term insulin-like effects of monoamine oxidases and semicarbazide-sensitive amine oxidase substrates in cultured adipocytes. Metabolism 55: 1397-1405.    
  • 17. Visentin V, Marq P, Bour S, et al. (2003) Effect of prolonged treatment with tyramine on glucose tolerance in streptozotocin-induced diabetic rats. J Physiol Biochem 59: 225-232.    
  • 18. Visentin V, Bour S, Boucher J, et al. (2005) Glucose handling in streptozotocin-induced diabetic rats is improved by tyramine but not by the amine oxidase inhibitor semicarbazide. Eur J Pharmacol 522: 139-146.    
  • 19. Lino CdS, Sales TdP, Gomes PB, et al. (2007) Anti-diabetic activity of a fraction from Cissus verticillata and tyramine, its main bioactive constituent, in alloxan-induced diabetic rats. Am J Pharmacol Toxicol 2: 178-188.    
  • 20. Carpéné C, Schaak S, Guilbeau-Frugier C, et al. (2016) High intake of dietary tyramine does not deteriorate glucose handling and does not cause adverse cardiovascular effects in mice. J Physiol Biochem 72: 539-553.    
  • 21. Iffiu-Soltesz Z, Prévot D, Carpéné C (2009) Influence of prolonged fasting on monoamine oxidase and semicarbazide-sensitive amine oxidase activities in rat white adipose tissue. J Physiol Biochem 65: 11-23.    
  • 22. Carpéné C, Galitzky J, Saulnier-Blache JS (2016) Short-term and rapid effects of lysophosphatidic acid on human adipose cell lipolytic and glucose uptake activities. AIMS Molec Sci 3: 222-237.    
  • 23. Atgié C, Sauvant P, Ambid L, et al. (2009) Possible mechanisms of weight loss of Siberian hamsters (Phodopus sungorus sungorus) exposed to short photoperiod. J Physiol Biochem 65: 377-386.    
  • 24. Fowler CJ, Tipton KF (1981) Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem Pharmacol 30: 3329-3332.    
  • 25. Carpéné C, Les F, Hasnaoui M, et al. (2016) Anatomical distribution of primary amine oxidase activity in four adipose depots and plasma of severely obese women with or without a dysmetabolic profile. J Physiol Biochem 73: 475-486.    
  • 26. Prévot D, Soltesz Z, Abello V, et al. (2007) Prolonged treatment with aminoguanidine strongly inhibits adipocyte semicarbazide-sensitive amine oxidase and slightly reduces fat deposition in obese Zucker rats. Pharmacol Res 56: 70-79.    
  • 27. Yraola F, Garcia-Vicente S, Marti L, et al. (2007) Understanding the mechanism of action of the novel SSAO substrate (C7NH10)6(V10O28).2H2O, a prodrug of peroxovanadate insulin mimetics. Chem Biol Drug Des 69: 423-428.
  • 28. Gilliam LK, Palmer JP, Taborsky GJ, Jr. (2007) Tyramine-mediated activation of sympathetic nerves inhibits insulin secretion in humans. J Clin Endocrinol Metab 92: 4035-4038.    
  • 29. Carpéné C, Iffiú-Soltész Z (2011) Monoaminergic systems and anti-obesity drug discovery: chronic administration of sympathicomimetic amines, re-uptake inhibitors, or amine oxidase inhibitors? In: Anti-Obesity Drug Discovery and Development (Atta-ur-Rahman & Iqbal Choudhary M Editors) Bentham Sciences Publishers 1: 114-130.
  • 30. Suzzi G (2003) Biogenic amines in dry fermented sausages: a review. Int J Food Microbiol 88: 41-54.    
  • 31. Til HP, Falke HE, Prinsen MK, et al. (1997) Acute and subacute toxicity of tyramine, spermidine, spermine, putrescine and cadaverine in rats. Food Chem Toxicol 35: 337-348.    
  • 32. Yonekura T, Kamata S, Wasa M, et al. (1988) Simultaneous determination of plasma phenethylamine, phenylethanolamine, tyramine and octopamine by high-performance liquid chromatography using derivatization with fluorescamine. J Chromatogr 427: 320-325.    
  • 33. VanDenBerg CM, Blob LF, Kemper EM, et al. (2003) Tyramine pharmacokinetics and reduced bioavailability with food. J Clin Pharmacol 43: 604-609.    
  • 34. Korn A, Da Prada M, Raffesberg W, et al. (1988) Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. J Neural Transm Suppl 26: 57-71.
  • 35. McDonald GR, Hudson AL, Dunn SM, et al. (2008) Bioactive contaminants leach from disposable laboratory plasticware. Science 322: 917.    
  • 36. Mundinger TO, Cummings DE, Taborsky GJ (2006) Direct stimulation of ghrelin secretion by sympathetic nerves. Endocrinology 147: 2893-2901.    
  • 37. Adams F, Boschmann M, Schaller K, et al. (2006) Tyramine in the assessment of regional adrenergic function. Biochem Pharmacol 72: 1724-1729.    
  • 38. Morin N, Visentin V, Calise D, et al. (2002) Tyramine stimulates glucose uptake in insulin-sensitive tissues in vitro and in vivo via its oxidation by amine oxidases. J Pharmacol Exp Ther 303: 1238-1247.    
  • 39. Bairras C, Ferrand C, Atgié C (2003) Effect of tyramine, a dietary amine, on glycerol and lactate release by isolated adipocytes from old rats. J Physiol Biochem 59: 161-167.    
  • 40. Stohs SJ, Hartman MJ (2015) A review of the receptor binding and pharmacological effects of N-methyltyramine. Phytother Res 29: 14-16.    
  • 41. Hamasaki H (2016) Functional foods for type 2 diabetes. AIMS Med Sci 3: 278-297.    

 

Reader Comments

your name: *   your email: *  

Copyright Info: © 2017, Christian Carpéné, et al., licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution Licese (http://creativecommons.org/licenses/by/4.0)

Download full text in PDF

Export Citation

Copyright © AIMS Press All Rights Reserved